EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.7.1.149 | Alzheimer Disease |
11241393 |
Cl(-)-ATPase in rat brain and kidney. |
unassigned |
0 |
| 2.7.1.149 | Amyotrophic Lateral Sclerosis |
30741620 |
VAMP associated proteins are required for autophagic and lysosomal degradation by promoting a PtdIns4P-mediated endosomal pathway. |
ongoing research
unassigned |
1
0 |
| 2.7.1.149 | Astrocytoma |
10411568 |
Inhibition of beta(2)-adrenergic and muscarinic cholinergic receptor endocytosis after depletion of phosphatidylinositol bisphosphate. |
unassigned |
0 |
| 2.7.1.149 | Autoimmune Diseases |
34312224 |
PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity. |
causal interaction
diagnostic usage
unassigned |
2
3
0 |
| 2.7.1.149 | Bacterial Infections |
23608234 |
Mammalian phosphatidylinositol 4-kinases as modulators of membrane trafficking and lipid signaling networks. |
causal interaction
unassigned |
4
0 |
| 2.7.1.149 | Breast Neoplasms |
24127122 |
Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression. |
causal interaction
diagnostic usage
ongoing research
unassigned |
4
3
4
0 |
| 2.7.1.149 | Breast Neoplasms |
24209622 |
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. |
ongoing research
unassigned |
3
0 |
| 2.7.1.149 | Breast Neoplasms |
28123587 |
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma. |
diagnostic usage
ongoing research
unassigned |
4
4
0 |
| 2.7.1.149 | Carcinogenesis |
27132569 |
PIP4K2B: Coupling GTP Sensing to PtdIns5P Levels to Regulate Tumorigenesis. |
causal interaction
unassigned |
1
0 |
| 2.7.1.149 | Carcinogenesis |
30697230 |
Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
3
3 |
